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Abstract
Background: Travellers infected with Schistosoma spp. might be pauci- or even asymptomatic on first presentation.
Therefore, schistosomiasis may remain undiagnosed in this population. Active infection, as evidenced by the
presence of the tissue-dwelling worm, can be demonstrated via the detection of adult worm-derived circulating
anodic antigen (CAA) utilising a robust well-described lateral flow-(LF) based test applying background-free up-
converting reporter particles (UCP). In this prospective study, we assessed the diagnostic value of serum and
urine UCP-LF CAA test in comparison with two Schistosoma-specific serological assays detecting antibodies
against adult worm antigen-immuno fluorescence assay (AWA-IFA) and against soluble egg antigen–enzyme-linked
immunosorbent assay (SEA-ELISA) antigens in travellers.
Methods: Samples were collected from 106 Dutch travellers who reported freshwater contact in sub-Saharan Africa
and who were recruited up to 2 years after return. Subjects were asked to complete a detailed questionnaire on
travel history, water contact, signs and symptoms compatible with schistosomiasis.
Results: Two travellers were positive by serum CAA and an additional one by urine CAA. A total of 22/106 (21%)
samples were antibody positive by AWA-IFA and 9/106 (9%) by SEA-ELISA. At follow-up 6 weeks and 6 months
after praziquantel treatment, all seropositives remained antibody positive whereas CAA was cleared. Seropositivity
could not be predicted by the type of fresh water-related activity, country visited or symptoms reported.
Conclusion: The low number of UCP-LF CAA positives suggests that in travellers, active infections often do not
establish or have very low worm burden. Based on our high seroconversion rates, we conclude that the AWA-IFA
assay is the most sensitive test to detect schistosome exposure. Given the lack of predictive symptoms or risk
factors, we recommend schistosomiasis screening at least by serology in all travellers with reported freshwater
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Introduction
Schistosomiasis is an infectious tropical disease caused by par-
asites of the genus Schistosoma, affecting ∼260 million people
worldwide.1 The endemicity of schistosomiasis, mainly Schis-
tosoma mansoni and Schistosoma haematobium, is focal and
depends on the presence of the freshwater snail intermediate
hosts. With increasing tourism to sub-Saharan Africa, schisto-
somiasis occurs more frequently in travellers after swimming in
freshwater bodies.2 ,3 Schistosomiasis in travellers differs from
what is seen in endemic populations and may present as an
acute or chronic disease, with or without stage-specific typical
signs and symptoms.4–8 Because many physicians are unfamiliar
with the disease and eosinophilia in early infection is infrequent,
schistosomiasis in travellers remains underdiagnosed.9 Incidence
studies for schistosomiasis in travellers are rare, making it diffi-
cult to develop screening algorithms.6 If left untreated, chronic
schistosomiasis can cause late genitourinary, gastrointestinal or
neurological morbidity.5
The classic diagnosis of schistosomiasis is based on micro-
scopic detection of ova in stool or urine, although microscopy
lacks sensitivity and requires multiple consecutive samples par-
ticularly when the worm burden is low.10 Consequently, the
detection of schistosome-specific antibodies (Abs) plays a promi-
nent role in the diagnosis of acute schistosomiasis in travellers.
However, serological titres are not related to worm intensity and
remain positive over years, making serology an inadequate tool
to discern an active infection from a past infection or to monitor
cure.11 ,12
Alternatively, active infections, as defined by the presence of
viable worms, can be visualized by the quantification of genus-
specific antigens originating from the gut of the adult worm in the
host circulatory system.13 One of these antigens, the circulating
anodic antigen (CAA), can be detected in serum and urine
through a highly specific and ultra-sensitive lateral flow (LF) test
that applies up-converting reporter particles (UCP).14 ,15 By uti-
lizing this UCP-LF CAA assay, active Schistosoma infections can
be demonstrated within weeks after exposure.16 ,17 In addition,
CAA concentrations decline rapidly following successful treat-
ment, making the UCP-LF CAA assay highly suitable to monitor
cure.17
Establishing a reliable test, which confirms cure, remains a
therapeutic necessity in the treatment of travellers.18 ,19 Treatment
relies on the use of a single oral drug, praziquantel (PZQ). At the
recommended single dose of 40 mg/kg, failures are frequent.20
The single dose is recommended based on its use for mass admin-
istration in controlled programmes; however, required doses to
achieve 100% cure of individual patients has not been well
established.21
In order to address the current knowledge gaps in the screen-
ing, diagnosis and treatment of travellers for schistosomiasis, we
have prospectively followed travellers with reported freshwater
contact in sub-Saharan Africa. This unique data set allows us
to (i) identify risk factors for schistosomiasis in travellers, (ii)
explore the use of the UCP-LF CAA assay in the context of
established serological assays for travellers and (iii) determine
the cure rates after conventional PZQ treatment.
Materials and methods
Study design and participants
Travellers were recruited through advertisements at the travel
clinics and infectious diseases outpatient departments of the Lei-
den University Medical Centre, the Amsterdam University Med-
ical Centres and the Harbour Hospital in Rotterdam between
November 2014 and April 2019. Travellers with reported fresh-
water contact in sub-Saharan Africa were requested to partic-
ipate in the study and were offered free diagnostic evaluation.
Travellers were asked to complete a detailed questionnaire about
their exposure history and about their previous and current
related signs and symptoms, as well as to donate blood, urine
and stool for diagnosis between 12 weeks and 2 years after
the last self-reported freshwater contact. Inclusion criteria were:
(i) travellers with self-reported freshwater contact in the past
2 years at a site known for schistosomiasis endemicity in sub-
Saharan Africa, regardless of signs or symptoms, (ii) agreement
to undergo study procedures (serology) and (iii) willingness to
provide a maximum of three additional blood samples. Travellers
were excluded from participation when (i) previously treated
for schistosomiasis, (ii) known to be positive for schistoso-
miasis serology before last water contact at endemic site or
(iii) using immunosuppressive or immunomodulatory drugs at
presentation, as this could compromise the interpretation of
schistosomiasis serological findings.
All travellers with positive Schistosoma serology were treated
with 40 mg/kg of PZQ at least once and were asked to donate
another sample of serum and urine at 6 weeks and 6 months after
treatment (Table 1, overview of samples taken). At 6 weeks after
treatment, some travellers received another dose of 40 mg/kg of
PZQ as per discretion of the treating physician.
All participants provided informed consent. The study was
approved by the LUMC Institutional Medical Ethical Research
Committee (P14.239, clinicaltrials.gov NCT02194712) and
endorsed by the respective institutional boards of the other
partaking centres.
Serological assays
An immunofluorescence assay (IFA) was used for the detection of
Schistosoma-specific Immunoglobulin M (IgM Abs) against car-
bohydrate epitopes of gut-associated adult worm antigen (AWA)
as previously described.17 ,22 In brief, Rossman’s fixed adult S.
mansoni worm sections were incubated with 2-fold dilution
series of serum starting at a 1:8 dilution. Following incubation
with goat anti-human IgM (μ-chain specific)–fluorescein isoth-
iocyanate (FITC) antibody Sigma-Aldrich; F5384), slides were
examined by fluorescence microscopy. The titre was determined
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Table 1. Summary of sample collection and diagnostic tests
performed over time










In case of Ab positivity
PZQ (40 mg/kg) X
Ab diagnostics X X
Serum/Urine CAA X X
worm gut epithelium was still visible. A negative control and
a positive reference serum were run in parallel at each slide.
Samples were considered to be positive at a titre > 1:8.
An enzyme-linked immunosorbent assay (ELISA) was used
for the detection of Schistosoma-specific IgG Abs directed
against S. mansoni soluble egg antigen (SEA) as previously
described.17 ,23 In brief, crude SEA was prepared from S. mansoni
eggs recovered from the livers of infected hamsters, and diluted
to a concentration of 5 μg protein/ml for overnight coating of
96 well plates (Polysorb Nunc) and stored until use.24 ,25 After
thawing, plates were washed and blocked in 1% bovine serum
albumin (BSA) in phosphate-buffered saline (PBS) after which
they were incubated with a dilution series of serum samples
(1:16 until 1:2048 in PBS/Tween 0.05/5% foetal calf serum).
After washing and staining with secondary antibody (mouse
anti-human IgG alkaline phosphatase 1:10.000, Sigma-Aldrich;
A2064), para-nitrophenylphosphate substrate (Sigma-Aldrich;
P5994) was added for Ab detection. A negative control and a
positive reference serum were run in parallel on each plate. The
titre was determined as the dilution of the sample at which the
extinction is higher or equal to the reference standard. Samples
were considered positive showing a titre > 1:16.
Both the AWA-IFA and the SEA-ELISA are in-house tests,
which have been implemented at the LUMC as routine diag-
nostic tests for the serological diagnosis of schistosomiasis sev-
eral decades ago. They fulfil all laboratory quality assessment
requirements (ISO 15189:2012 certified), including successful
participation in an external quality assessment scheme (UK
NEQAS).
Antigen detection assay
CAA concentrations were determined in serum (0.5 ml;
SCAA500 format) and urine (2 ml; UCAA2000 format) using
the dry format of the UCP-LF CAA assay as described before.15
In brief, samples were pre-treated with trichloroacetic acid
(TCA) in order to remove interfering proteins and to dissociate
potential immune complexes. Following a centrifuge step and
concentrating the supernatant, the samples were left to incubate
1 h after which a LF strip was placed in each well of a microtitre
plate. The strips were scanned for UCP reporter signals with a
dedicated Packard FluoroCount strip reader.14
Results were reported quantitatively expressed as CAA levels
in pg/ml serum. A TCA-soluble fraction with known CAA con-
centration was used as a reference standard for the quantification
of the antigen.14 ,15 Serum CAA concentrations above 3 pg/ml and
urine CAA concentration above 0.3 pg/ml were used as cut-off
values indicating active infection.15
Microscopy and DNA detection
Only a single stool sample and a single urine sample collected
before treatment were included in the analysis. Stool and urine
samples were examined for the presence of Schistosoma eggs
via microscopy performed according to the procedure of the
centre where the study participant was recruited. To detect the
presence of Schistosoma DNA in stool or urine, a real-time
polymerase chain reaction (PCR) analysis targeting the internal
transcribed spacer (ITS-2) gene was performed. Sample handling,
DNA extraction and PCR analysis were performed as previously
described.26 ,27
Sample size calculation
Based on a previously reported incidence study, we estimated
a positive serology of ∼50% after freshwater contact.9 We
aimed to include 155 travellers, which allowed us to determine
sensitivity and specific of the UCP-LF CAA assay as compared
to serology at an estimated 95% with 5% confidence interval.
Because of slow recruitment rates, we were only able to include
106 travellers within the pre-specified time period.
Data analysis
Data were collected using Castor EDC.28 Analyses were per-
formed using IBM SPSS statistics for Windows, version 23.0
(IBM Corp., Armonk, NY, USA). P values were considered signif-
icant when P < 0.05. Proportions, means or where appropriate
medians and interquartile range (IQR) were calculated. Signifi-




A total of 106 Dutch travellers of which 41 (39%) were male and
65 (61%) were female, with a median age of 32.5 years (range,
20–70 years) were enrolled into the study (Figure 1, Table 2). All
the study participants reported predefined freshwater contact at
least once within 2 years before inclusion in the study, as per
study protocol.
Participants filled out their travel history and freshwater
exposures in a detailed questionnaire. The most frequently
reported freshwater source was Lake Malawi (51/106; 48%)
followed by Nile River (25/106; 24%) and Lake Victoria
(11/106; 10%). The most frequently reported freshwater
activities were swimming 76/106 (72%), showering 57/106
(54%) and wading 28/106 (27%). Travellers stayed at their
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Figure 1. Study flowchart detailing study participation of Dutch travellers for submitting serum and urine samples for the diagnosis of schistosomiasis
before and after administration of PZQ during 2014–2019. Asterisk represents schistosomiasis Ab diagnostics via AWA-IFA and SEA-ELISA
(IQR) = 14–79 days]. Seropositives stayed longer (median
75 days) at their travel destination than seronegatives (median
22 days) (P < 0.05). No differences were seen in self-reported
length for freshwater contact between seronegatives [median
4 days; (IQR) = 2–29] and seropositives [median 17 days;
(IQR) = 2–137].
A total of 24/106 (23%) travellers reported signs and
symptoms that could indicate schistosomiasis, of which 7 had
detectable anti-Schistosoma antibodies. Eleven participants
reported rash after freshwater contact and three out of
those were antibody positive. Fatigue (16, 15%), abdominal
pain (11, 10%), diarrhoea (10, 9%), myalgia (8, 8%) and
headache (7, 7%) were the most frequently reported symptoms
(Table 2).
Serological data
At baseline, 21 of the 106 sera (20%) tested Ab positive in
the AWA-IFA, whereas 9 (9%) tested positive in the SEA-ELISA
(Table 3). There was one sample positive in SEA-ELISA, which
was negative in the AWA-IFA, making a total of 22 samples
(21%) positive in either antibody test at baseline.
Of the samples positive at baseline by AWA-IFA, two partic-
ipants (10%) had low antibody titres (1:16–1:64) whereas 12
(60%) had moderate (1:128–1:512) and six (29%) had high
(>1:512) IgM titres (Figure 2). For the SEA-ELISA, three samples
in each group had low, moderate and high antibody titres,
respectively. Samples with higher AWA-IFA titres generally also
had higher titres in the SEA-ELISA. The sample, which was
negative by AWA-IFA but positive by SEA-ELISA, had a titre
of 1:64. This particular traveller had been to Nile River and
reported water contact by swimming, showering and drinking
during 3 years without any symptoms. There was no follow-up
sample from this participant available.
Antigen detection
Only a small number of samples were found positive in antigen
detection assays; 2 positive sample (of 105 tested) in the UCP-LF
CAA serum assay and 1 positive sample (of 106 tested) in the
urine assay (Table 3). The two participants positive for serum
CAA (6.51 and 5.22 pg/ml) were also positive for AWA-IFA
(moderate and high antibody titres, respectively) and for SEA-
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Table 2. Demographic, travel-related characteristics, signs, symptoms and eosinophilia of 106 Dutch travellers
Serology + (n = 22) Serology − (n = 84) Risk (%)a
n % n %
Demographic Males (%) 7 31.8 34 40.5 17.1
Females (%) 15 68.2 50 59.5 23.1
Age (med) 29 33.5
Contact Place Malawi 6 27.3 45 53.6 11.8
Lake Victoria 3 13.6 8 9.5 27.3
Nile River 8 36.4 17 20.2 32.0
Omo Rivers, Ethiopia 2 9.1 0 0 100
Lake Tanganyika 2 9.1 2 2.4 50.0
Dogon, Mali 0 0 1 1.2 0
Zambezi River 0 0 5 6.0 0
Volta River, Ghana 1 4.5 3 3.6 25.0
Okavango Delta,
Botswana
0 0 3 3.6 0
Other 5 22.7 24 28.6 17.2
Water contact Swimming 21 95.5 55 65.5 27.6
Surfing 0 0 3 3.6 0
Diving 1 4.5 1 1.2 50.0
Wading 4 18.2 24 28.6 14.3
Showering 5 22.7 52 61.9 8.8
Drinking 3 13.6 5 6.0 37.5
Signs or Symptoms Signs or Symptoms
(Y/N)
7 31.8 17 20.2 29.2
Rash 3 13.6 8 9.5 27.3
Fever 2 9.1 1 1.2 66.7
Tiredness 4 18.2 12 14.3 25.0
Joint pain 1 4.5 7 8.3 12.5
Headache 2 9.1 5 6.0 28.6
Swelling 0 0 0 0
Coughing 3 13.6 2 2.4 60.0
Abdominal pain 4 18.2 7 8.3 36.4
Haematuria 0 0 1 1.2 0
Diarrhoea 2 9.1 8 9.5 20.0
None of the above 0 0 1 1.2 0
Eosinophils Eosinophils tested (%) 17 77.3 77 91.7
Positives (%) 6 35.3 3 3.9
Median (positives) 0.79 0.53
Range 0.5–0.88 0.51–0.86
IFA titres (range) 512–>1024 Neg.
ELISA titres (range) Neg.–1024 Neg.
Urine CAA (%) 1/6 (16.6) 0/3
Serum CAA (%) 0/6 0/3
aRisk defined as number of new cases of schistosomiasis confirmed by serology (IFA-AWA and ELISA-SEA) in a population at risk, divided by number of persons in that population at
risk.
and 0.06 pg/ml). The participant that was positive for urine CAA
(0.47 pg/ml) had serum CAA levels just below the threshold
(2.45 pg/ml) but was positive for both AWA-IFA (high antibody
titres) and SEA-ELISA (high antibody titres). In conclusion, none
of the three (serum or urine) positive samples by CAA were
negative in serological assays confirming the high specificity of
this test.
Risk factors for schistosomiasis in travellers
We investigated whether gender, age, geographical place, water
activity, signs or symptoms were risk factors for schistosomiasis
in travellers. There was no difference in gender or age between
those travellers who were seropositive either by AWA-IFA or by
SEA-ELISA (seropositives) and those who were seronegative.
Seropositives had more frequently been to the Nile River
(Uganda, 36%) and Lake Victoria (14%), whereas those that
were seronegative had most frequently visited Lake Malawi
(56%) (Table 2). The risk of seroconversion at these most
frequently visited sites culminated to 12–32% (Table 2).
In addition, seropositives were more frequently exposed to
freshwater by swimming (96 vs 66% in seronegatives), and less
so by showering (23 vs 62%) or wading (18 vs 29%). Roughly
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Table 3. Comparison between number of positives over time based on serology or CAA detection
n = 22 positives n = 22 positives
Baseline T+ 6 weeks T+ 6 months
Diagnostic Test Positives/tested % Positives/tested % Positives/tested %
AWA-IFA 21/106 19.8 15/15 100 8/8 100
SEA-ELISA 9/106 8.5 12/15 80 6/9 67
Serum CAA 2/105 1.9 0/14 0 0/8 0
Urine CAA 1/106 0.9 0/14 0 0/7 0
Cumulative
positive (%)a
22 20.8 15 14.2 8 7.5
aOut of 106 tested.
Figure 2. Antibody titres as measures by AWA-IFA (a) and SEA-ELISA (b) at baseline, 6 weeks after PZQ treatment and 6 months after PZQ treatment.
The red line indicates threshold value for the test (AWA-IFA > 1:8 titre, SEA-ELISA > 1:16 titre)
compatible with schistosomiasis, whereas 20% in the seronega-
tive group (P > 0.05) also reported symptoms. Rash was reported
by equal numbers in the seropositive (14%) and seronegative
group (10%). In conclusion, no relationship was found between
signs and symptoms and seropositivity.
Eosinophilia was more often present in seropositive partic-
ipants (35%) as compared to seronegatives (3.9%, P = 0.01),
although eosinophil elevations were generally not high [seropos-
itives median 0.79 × 109/L; (IQR) = 0.66–0.82 vs seronegatives
median 0.53 × 109/L; (IQR) = 0.51–0.53]. The risk of serconver-
sion when having eosinophilia was 67%.
The three travellers who had detectable CAA in serum (n = 2)
or urine (n = 1) were all women, symptomatic and swam in
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Malawi; the other had been to both Lake Victoria and Nile River
and had the highest eosinophil counts (0.88 × 109/L).
Microscopy and PCR
Stool and urine samples were examined at baseline for intestinal
and urinary schistosomiasis, respectively, by microscopy and
PCR. No eggs were detected out of 9 stool specimen or in 77
urine samples tested. PCR was performed in 11 stools and 67
urines, with detectable Schistosoma DNA in one stool sample.
This traveller had been exposed for 8 years in the Nile River
and Ethiopia (Omo rivers) and showed high IFA titres and high
ELISA titres but negative CAA antigen.
Post-treatment follow-up
All travellers who were seropositive were treated with 40 mg/kg
PZQ and checked for antibody and antigen CAA detection
6 weeks after treatment. At that time, all samples were nega-
tive by antigen detection assays (Supplementary Figure 1) and
remained so for 6 months. However, antibody levels persisted
whereby none of the seropositives or seronegatives seroconverted
by AWA-IFA after 6 weeks (Figure 2). Quantitatively, 4/15 had
increasing AWA-IFA titres, 5/15 had equal titres and 6/15 titres
had declined (Figure 2). SEA-ELISA titres were more variable,
five seronegative travellers seroconverted and were seropositive
(3 low, 1 moderate and 1 high titres) at follow-up (Figure 2).
All of these were moderate (n = 4) to high (n = 1) positive in
AWA-IFA at baseline. Of those travellers who were persistent
seropositive SEA-ELISA between baseline and 6 weeks after
treatment, one increased in titre, four persisted at the same level
and two declined.
Six months after the treatment, titres in the AWA-IFA
decreased with low (n = 2) and moderate (n = 6) titres, but none
converted to seronegative. IgG titres by SEA-ELISA showed six
out of 9 (67%) samples still positive at low (n = 4) and moderate
(n = 2) titres (Supplementary Table 1).
Discussion
This study is the first of its kind to prospectively assess the value
of circulating antigen detection in addition to antibody detection
as diagnostic tool for schistosomiasis in travellers with fresh-
water contact in sub-Saharan Africa. Because of its prospective
nature, we were able to analyse risk factors for schistosomiasis
in travellers and explore the practical use of UCP-LF CAA dry
assay format for travellers before and after treatment.
In the current study, we found AWA-IFA to be the most
sensitive test for detecting exposure to schistosomes, detecting
21 positives out of 106 travellers. The seroconversion of SEA-
ELISA typically occurs later.16 As previously reported, serological
assays are known to be the most sensitive and specific methods
for testing of travellers for schistosome exposure.10 ,13 Our study
furthermore confirmed that AWA-IFA titres remain at high levels
over a longer period over time and are even detectable 6 months
after treatment despite the fact that IgM Ab are usually short
lived.17 The serological data also confirmed that seroconversion
can be confidently assessed from 12 weeks after exposure. Earlier
studies from LUMC (Parasitology Department, The Nether-
lands) demonstrate that seroconversion in the AWA-IFA assay
can even occur as early as 4–6 weeks after exposure.17 This
contrasted with the kinetics of the IgG Ab against SEA, which
were more variable over time and seroconversion was assessed
in some cases even after treatment.12 ,13 ,16 ,17 Taken together, our
data validate the excellent application of serological assays and
the superior performance of the in-house IFA-AWA as compared
to the SEA-ELISA for screening purposes, but the inevitable
shortcoming of these serological assays in discerning active from
past infections.11 ,12 ,17
With the serum and urine antigen tests (UCP-LF CAA), we
found only 3 out of 22 seropositive patients to have active
infections. Possibly, worm burden in this population of travellers
is typically low or self-cleared. In animal models the percent-
age of cercariae developing into adult worms is generally low
(11–39%), highlighting the difference between exposure and
active infection.29 The UCP-LF CAA assay has proven better
sensitivity than traditional methods to detect active infection and
is applicable to all schistosome species.15 Of note, the use of
serum CAA and urine CAA dry reagent format, as deployed here,
facilitates implementation into routine diagnostic laboratories.
Better sensitivity can be achieved when using the wet reagent
format or higher samples volumes.15 ,17 The main advantage of
CAA detection as opposed to antibody detection is the potential
to follow up after treatment those who are antibody positive in
order to monitor cure. In doing so, we found all travellers to have
cleared CAA after a single dose of 40 mg/kg PZQ.
These data reignite the discussion around the PZQ dose reg-
imens. The World Health Organization (WHO) recommended
treatment schedule is 40 mg/kg PZQ twice with a 6-week inter-
val. However, the low CAA levels from our study population
suggest that treatment with 40 mg/kg PZQ only once may be
sufficient for most travellers. Alternatively, one could consider
testing for CAA after the first PZQ dose. If CAA levels at that
time are still detectable, a second round of PZQ treatment can
be provided.
Our results showed no clear risk factors that predict seropos-
itivity for schistosomiasis based on type of water contact or the
location where freshwater contact took place. Although some
locations such as Lake Malawi have previously been identified
as high-risk spots for travellers, it seems that the overall risk of
acquiring schistosomiasis at these ‘hotspots’ is somewhat lower
than previously estimated.9 A possible explanation could be the
reduced sensitivity of our serological assays for S. haematobium
or a differential risk for specific tourist spots around the same
water body. In addition, different types of water activities seem
to have similar risks. Unfortunately, we did not collect data on
the frequency and duration of the water contact, which might
increase cumulative risk. Moreover, the symptomology in the
questionnaire was asked without a specific time-frame and that
could lead to the unspecific nature of symptoms. Also, the use of
a towel, previously reported to significantly reduce the risk, had
not been recorded in the study.30 However, we did find a longer
travel duration for the seropositives as compared to the seroneg-
atives, indicating that the time spend in schistosome-endemic
destinations generally increases risks.31
We found similar rates of symptoms as previously reported
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fact that symptomatic subjects are more likely to participate in
these type of studies and are more likely to report. Surprisingly,
we found very little difference in the occurrence of symptoms
between seropositive and seronegative individuals. Fatigue and
abdominal pain were the most frequent symptoms, which con-
trasts the general notion that fever is the most frequently reported
symptom of travellers, although fatigue has been reported as
a hallmark for acute schistosomiasis before.4 ,31–33 As expected,
the frequency of eosinophilia was very low (35% of seroposi-
tives). Taken together, these data suggest that there is no clear
anamnestic feature to predict seropositivity in travellers with
reported water contact and thus we recommend screening in
all individuals with fresh water contact in endemic areas from
12 weeks after return.
In conclusion, the AWA-IFA showed the highest sensitivity for
use as a screening assay and can be confidently performed from
12 weeks after exposure onwards. CAA detection may be par-
ticularly useful to determine the worm burden and to point out
the possible need of a second treatment rounds with PZQ. Given
the high rates of seropositivity and the lack of anamnestic risk
factors (albeit exposure or symptoms), we recommend antibody
screening in all travellers with reported freshwater contact in
Schistosoma-endemic areas, preferably followed by CAA antigen
detection.
Supplementary data
Supplementary data are available at JTM online.
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